Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Open access
Gray, Jhanelle E., Heist, Rebecca S., Starodub, Alexander N., Camidge, D. Ross, Kio, Ebenezer A., Masters, Gregory A., Purcell, W. Thomas, Guarino, Michael J., Misleh, Jamal, Schneider, Charles J., Schneider, Bryan J., Ocean, Allyson, Johnson, Tirrell, Gandhi, Leena, Kalinsky, Kevin, Scheff, Ronald, Messersmith, Wells A., Govindan, Serengulam V., Maliakal, Pius P., Mudenda, Boyd, Wegener, William A., Sharkey, Robert M., Goldenberg, David M.·2017·Clinical Cancer Research

Abstract

Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients. Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who received either 8 or 10 mg/kg i.v. on days 1 and 8 of 21-day cycles. The primary endpoints were safety and objective response rate (ORR); duration of response, progression-free survival (PFS), and overall survival (OS) were secondary endpoints. Results: Sixty percent of patients showed tumor shrinkage from baseline CTs. On an intention-to-treat basis (N = 50), the ORR was 14% (17% for the 10-mg/kg group); the median response duration, 5.7 months; the clinical benefit rate (CBR ≥4 months), 34%; median PFS, 3.7 months; and median OS, 7.5 months. There was a suggested improvement in PR, CBR, and PFS with sacituzumab govitecan in second-line patients who were sensitive to first-line therapy, but no difference between first-line chemosensitive versus chemoresistant patients in the overall population. There was a statistically significant higher OS in those patients who received prior topotecan versus no topotecan therapy in a small subgroup. Grade ≥3 adverse events included neutropenia (34%), fatigue (13%), diarrhea (9%), and anemia (6%). Trop-2 tumor staining was not required for patient selection. No antibodies to the drug conjugate or its components were detected on serial blood collections. Conclusions: Sacituzumab govitecan appears to have a safe and effective therapeutic profile in heavily pretreated mSCLC patients, including those who are chemosensitive or chemoresistant to first-line chemotherapy. Additional studies as a monotherapy or combination therapy are warranted. Clin Cancer Res; 23(19); 5711–9. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0933

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 162

Metadata

Authors
Gray, J. E., Heist, R. S., Starodub, A. N., Camidge, D. R., Kio, E. A., Masters, G. A., Purcell, W. T., Guarino, M. J., Misleh, J., Schneider, C. J., Schneider, B. J., Ocean, A., Johnson, T., Gandhi, L., Kalinsky, K., Scheff, R., Messersmith, W. A., Govindan, S. V., Maliakal, P. P., Mudenda, B., Wegener, W. A., Sharkey, R. M., & Goldenberg, D. M.
Venue
Clinical Cancer Research
Published
2017-10-01
Volume
23
Issue
19
Pages
5711-5719
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2729256052
Cited by
162
References
2
FWCI
5.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0933
The paper
Gray, J. E., Heist, R. S., Starodub, A. N., Camidge, D. R., Kio, E. A., Masters, G. A., Purcell, W. T., Guarino, M. J., Misleh, J., Schneider, C. J., Schneider, B. J., Ocean, A., Johnson, T., Gandhi, L., Kalinsky, K., Scheff, R., Messersmith, W. A., Govindan, S. V., Maliakal, P. P., . . . Goldenberg, D. M. (2017). Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0933

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.